307 related articles for article (PubMed ID: 15373015)
1. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
2. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
3. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
4. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
5. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
7. Strategies for ovarian cancer prevention.
Dann RB; Kelley JL; Zorn KK
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
9. A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision.
Friedenson B
MedGenMed; 2001 Nov; 3(6):2. PubMed ID: 11965197
[TBL] [Abstract][Full Text] [Related]
10. Improving surveillance and quality of life of BRCA mutation carriers.
Loman N; Borg A
J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
[No Abstract] [Full Text] [Related]
11. [Inherited breast and ovarian cancers].
Gerdes AM; Ejlertsen B
Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
[TBL] [Abstract][Full Text] [Related]
12. Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off?
Masciari S; Garber JE
J Clin Oncol; 2005 Oct; 23(28):6817-9. PubMed ID: 16157931
[No Abstract] [Full Text] [Related]
13. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
14. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
[No Abstract] [Full Text] [Related]
15. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
16. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer risk: evaluating the risk and role of genetic testing.
Craft M; Mulvihill J
J Okla State Med Assoc; 2002 Oct; 95(10):663-4; quiz 665-6. PubMed ID: 12420416
[TBL] [Abstract][Full Text] [Related]
18. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
19. Breast & ovarian cancer. Issues in risk assessment.
Caro SW
Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
[No Abstract] [Full Text] [Related]
20. Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E; Plon SE
Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
[No Abstract] [Full Text] [Related]
[Next] [New Search]
